Allyhiani Moayad, Kurdi Ahmad, Abdulaziz Akrm, Faqeh Sultan, Alhajjaji Abdulrahman, Alansari Safwan, Althaqafi Abdulrhman, Alzaman Naweed, Ali Majid
College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Department of Pharmaceutical Care, Al Noor Specialist Hospital, Makkah, Saudi Arabia.
Saudi Pharm J. 2022 Feb;30(2):112-119. doi: 10.1016/j.jsps.2021.12.019. Epub 2021 Dec 31.
There are limited studies that address the use of newer antidiabetics by prescribers in Saudi Arabia and their adoption of the newer diabetes guidelines. The primary aim of our study was to explore the prescribing patterns of first- and second-line agents for the management of type 2 diabetes and the factors affecting them.
A cross-sectional self-administered survey was designed to collect responses from the prescribers in the Makkah Region of Saudi Arabia from 16 February through 16 June 2021. The questionnaire was developed in the English language, piloted, and tested for validity. Participants were recruited on a convenience sampling basis, and the data were collected by visiting them in-person.
A total of 103 prescribers responded to the survey. The majority of the respondents were male (69%), Saudi nationals (54%), practicing in Makkah city (62%), working in the government sector (62%), and had the prescribing experience of 1-5 years (37%). Metformin (95%) was the respondents' most preferred first-line drug of choice, followed by sulfonylureas (5%). When the first-line was contraindicated, sulfonylureas (30%) were considered the most preferred drug of choice, followed by DPP4 inhibitors (25%) and SGLT2 inhibitors (16%), respectively. When the first-line was not sufficient to control diabetes, sulfonylureas (32%) and DPP4 inhibitors (31%) were considered the most preferred drugs of choice as an add-on therapy. SGLT2 inhibitors (31%) and metformin (24%) were considered the preferred first-line choices if the patient had an established cardiovascular disease.
Sulfonylureas were found to be the most considered choice as second-line therapy. There is a need to provide targeted education to the prescribers related to the newer diabetes guidelines in order to promote the use of more evidence-based and safer antidiabetics.
关于沙特阿拉伯处方医生使用新型抗糖尿病药物及其采用新糖尿病指南的研究有限。我们研究的主要目的是探讨用于管理2型糖尿病的一线和二线药物的处方模式及其影响因素。
设计了一项横断面自填式调查，以收集2021年2月16日至6月16日期间沙特阿拉伯麦加地区处方医生的回复。问卷以英语编制，进行了预试验并测试了有效性。参与者采用便利抽样法招募，通过亲自拜访他们来收集数据。
共有103名处方医生回复了调查。大多数受访者为男性（69%），沙特国民（54%），在麦加市执业（62%），在政府部门工作（62%），处方经验为1至5年（37%）。二甲双胍（95%）是受访者首选的一线药物，其次是磺脲类药物（5%）。当一线药物禁忌时，磺脲类药物（30%）被认为是最首选的药物，其次分别是二肽基肽酶4抑制剂（DPP4抑制剂，25%）和钠-葡萄糖协同转运蛋白2抑制剂（SGLT2抑制剂，16%）。当一线药物不足以控制糖尿病时，磺脲类药物（32%）和DPP4抑制剂（31%）被认为是作为附加治疗的最首选药物。如果患者患有已确诊的心血管疾病，SGLT2抑制剂（31%）和二甲双胍（24%）被认为是首选的一线药物。
磺脲类药物被发现是二线治疗中最常被考虑的选择。有必要针对处方医生提供与新糖尿病指南相关的针对性教育，以促进使用更具循证依据且更安全的抗糖尿病药物。
